Viking therapeutics stocks.

Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes. Viking Therapeutics (NASDAQ:VKTX) has observed the following analyst ratings within the last quarter: These 11 analysts have an average price target of $26.09 versus the current price of Viking ...Jan 24, 2022 · Investors didn't exactly launch a raid on Viking Therapeutics ( VKTX 6.23%) stock during Monday's trading session. The shares tumbled by nearly 7% on the back of discouraging news about one of the ... The 11.59 million shares sold short account for 12.3% of Viking Therapeutics stock's available float, or roughly three days' worth of pent-up buying power. The equity's usually quiet options pits ...

Viking Cruises, known for their luxurious and culturally immersive voyages, has announced their 2023 cruise itineraries. Amongst them are several exciting options for those who dream of exploring the stunning fjords of Scandinavia.Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. ( NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent …

The Viking Therapeutics stock price gained 0.94% on the last trading day (Wednesday, 29th Nov 2023), rising from $11.72 to $11.83. During the last trading day the stock fluctuated 4.26% from a day low at $11.74 to a day high of $12.24. The price has been going up and down for this period, and there has been a 5.91% gain for the last 2 weeks.Sep 21, 2023 · As of September 20, 2023, shares of Viking Therapeutics opened at $13.80 on Wednesday. Over the past twelve months, the stock has experienced a low of $2.53 and a high of $25.72. The current trading price places it closer to its low point for the year. Viking Therapeutics has shown stability in its moving averages over recent periods.

Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. The consensus among analysts is that Viking Therapeutics Inc (VKTX) is a Buy stock at the moment, with a recommendation rating of 1.09. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 11 have rated it as a Hold, with 10 advising it as a Buy. 0 have rated the stock as Underweight.Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ... Jun 17, 2023 · An up-and-coming stock with lots of potential is Viking Therapeutics (VKTX-2.28%).Investors have been piling money into the biotech stock this year, as it has surged 150% since January. And at a ...

Viking Thera stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Viking Therapeutics, Inc. is a biopharmaceutical company. The company is engaged in development of novel therapies for metabolic and endocrine disorders. Its product candidate consists of VK5211, VK0214, VK0612 and ...

The S&P 500 is up 15% this year, and there are many stocks that have been performing much better than that. Shares of Hims & Hers Health (HIMS 1.75%) and Viking Therapeutics (VKTX-2.54%) have been ...

Viking Therapeutics (VKTX 6.46%) ... R&D stage biotechs such as Viking. These risky stocks can generate substantial returns or wipe out entire investments. Thus, it may make sense to own a small ...Are you looking for a unique way to explore the world? Look no further than My Viking Cruise. With My Viking Cruise, you can experience the world in a whole new way. My Viking Cruise takes you on an adventure around the world, exploring som...The biotech's stock is heating up in response to a positive take by the private investment bank Roth Capital Partners. The firm initiated coverage today on Viking's stock, rolling out a $32 per ...The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Viking Therapeutics Inc 50-day moving average is $11.06.Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report. Eli Lilly and Company (LLY) : Free Stock Analysis Report. Viking Therapeutics, Inc. (VKTX) : Free Stock ...Mar 28, 2023 · 04:18 PM ET 03/28/2023. Viking Therapeutics ( VKTX) said Tuesday that recipients of its experimental obesity treatment lost up to 18 pounds, and VKTX stock catapulted to a five-year high. On today ...

As of September 20, 2023, shares of Viking Therapeutics opened at $13.80 on Wednesday. Over the past twelve months, the stock has experienced a low of $2.53 and a high of $25.72. The current trading price places it closer to its low point for the year. Viking Therapeutics has shown stability in its moving averages over recent periods.Viking Therapeutics, Inc. (VKTX) latest earnings report: revenue, EPS, surprise, history, news and analysis.Viking Therapeutics Stock Investing · Stocks . USA . ... Investing in stocks, such as Viking Therapeutics, is an excellent way to grow wealth. For long-term ...Thinking about trading options or stock in Tesla, Pfizer, Super Micro Computer, Viking Therapeutics, or Coinbase Global?Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine …Viking Therapeutics (NASDAQ:VKTX) has observed the following analyst ratings within the last quarter: These 11 analysts have an average price target of $26.09 versus the current price of Viking ...

Are you ready to embark on a journey of discovery and adventure? With the help of MyVikingJourney.com, you can do just that. This online platform provides users with the tools and resources they need to plan their perfect Viking voyage.Viking Therapeutics Stock Earnings. The value each VKTX share was expected to gain vs. the value that each VKTX share actually gained. Viking Therapeutics ( VKTX) reported Q3 2023 earnings per share (EPS) of -$0.23, missing estimates of -$0.22 by 3.04%. In the same quarter last year, Viking Therapeutics 's earnings per share (EPS) was -$0.21.

Stock Information; News & Events; SEC Filings; Analyst Coverage; Corporate Governance; Shareholder Services; Corporate Presentation; ContactToday, many people think of Vikings as a brutal culture consisting of hulking blonde men who raided villages and slaughtered everyone in their path. This larger-than-life persona also encourages the belief that Vikings were especially cruel...Jun 13, 2023 · Key Points. Amylyx Pharmaceuticals and Viking Therapeutics have been on fire over the past year. Even so, both companies still look incredibly undervalued relative to their long-term growth ... 04:18 PM ET 03/28/2023. Viking Therapeutics ( VKTX) said Tuesday that recipients of its experimental obesity treatment lost up to 18 pounds, and VKTX stock catapulted to a five-year high. On today ...Viking Therapeutics, Inc. ( NASDAQ:VKTX – Get Free Report )’s stock price fell 3.2% on Friday . The company traded as low as $11.82 and last traded at $11.83. 193,335 shares changed hands ...In recent news pertaining to Viking Therapeutics, CEO Brian Lian sold 79,336 shares of the company’s stock on Thursday, April 13th. With an average price per share of $18.45, this transaction amounted to a total value of $1,463,749.20. Following this sale, Lian now holds 2,307,963 shares of Viking Therapeutics’ stock valued at $42,581,917.35.Viking Therapeutics (NASDAQ:VKTX) has observed the following analyst ratings within the last quarter: These 11 analysts have an average price target of $26.09 versus the current price of Viking ...Shares of clinical-stage biotech Viking Therapeutics ( VKTX 7.03%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ...Mar 29, 2023 · That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...

Mar 29, 2023 · Key Points. Viking Therapeutics stock has already gained an astounding 463% in the past six months. With key data readouts in obesity and NASH on tap later this year, the small-cap biotech could ...

Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Turning to Viking Therapeutics' balance sheet, the company had cash and cash equivalents of $69.5M, and short-term investments – available-for-sale of $323.4M. The total of these assets is $392 ...Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 13.01 +0.79 (+6.46%) At close: 04:00PM EST. 13.10 +0.09 (+0.69%) After hours: 07:47PM...The goal of this activity is for learners to be better able to assess risk of fibrotic disease and make evidence-based treatment recommendations for patients with or at risk of nonalcoholic steatohepatitis (NASH). Upon completion of this activity, participants will: Have increased knowledge regarding the. Prevalence and risk factors for NASH.Find insights on Viking Therapeutics, Eli Lilly, 89bio, and more in the latest Market Talks covering the Health Care sector.Viking Therapeutics (NASDAQ:VKTX) has observed the following analyst ratings within the last quarter: These 4 analysts have an average price target of $17.5 versus the current price of Viking ...Sep 21, 2023 · As of September 20, 2023, shares of Viking Therapeutics opened at $13.80 on Wednesday. Over the past twelve months, the stock has experienced a low of $2.53 and a high of $25.72. The current trading price places it closer to its low point for the year. Viking Therapeutics has shown stability in its moving averages over recent periods. Viking Therapeutics showed promise in treating metabolic issues with its drug candidate VK2809. ... and stock analysis. Q2 2023 Earnings. Viking's latest earnings report revealed a Q2 2023 R&D ...The healthcare sector, for example, has been home to a number of low-priced stocks that eventually went on a major growth spurt. Not that long ago, Axsome Therapeutics and Viking Therapeutics were ...Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It looks like hedge funds own 5.9% of Viking Therapeutics shares.Today, many people think of Vikings as a brutal culture consisting of hulking blonde men who raided villages and slaughtered everyone in their path. This larger-than-life persona also encourages the belief that Vikings were especially cruel...

By Vlad Schepkov. Shares of Viking Therapeutics (NASDAQ: VKTX) are trading down over 15% late into Tuesday's session, in a move linked to the disappointing clinical data posted by VKTX's ...Shares of clinical-stage metabolism specialist Viking Therapeutics ( VKTX 0.94%) were up by 12.4%, on abnormally high volume, as of 3:12 p.m. ET Tuesday afternoon. The big gain came after the ...Jun 27, 2023 · Truist Financial analyst Joon Lee reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price target of $32.00.The company’s shares opened today at $17.72 ... Instagram:https://instagram. nysearca vtv comparecrowdfunding investment sitesinventory management software market sizetom wilson northrop grumman Viking Cruises, known for their luxurious and culturally immersive voyages, has announced their 2023 cruise itineraries. Amongst them are several exciting options for those who dream of exploring the stunning fjords of Scandinavia.To put that in perspective, Viking’s daily average trading volume is closer to 785,000 shares. VKTX stock is up 67.4% as of Monday morning and up 37.9% since the start of the year. Investors ... vanguard after hours tradingamericann Nov 22, 2023 · Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. Top healthcare stocks this month include Viking Therapeutics Inc., Cabaletta Bio Inc., and Prometheus Biosciences Inc., shares of which have soared more than 600% in the last year on promising ... hemmings car auctions Mar 16, 2023 · There has been no insider activity in Viking Therapeutics, Inc. stock since a director bought just over $110,000 worth of shares in early May of last year. The company ended the 2022 fiscal year ... Viking Therapeutics last announced its earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per …